The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Photo of Mattias Ohlsson

Mattias Ohlsson

Professor

Photo of Mattias Ohlsson

Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia

Author

  • Bob Olsson
  • Joakim Hertze
  • Mattias Ohlsson
  • Katarina Nägga
  • Kina Hoglund
  • Hans Basun
  • Peter Annas
  • Lars Lannfelt
  • Niels Andreasen
  • Lennart Minthon
  • Henrik Zetterberg
  • Kaj Blennow
  • Oskar Hansson
Show all

Summary, in English

Heart fatty acid binding protein (HFABP) is expressed in the brain and is elevated in cerebrospinal fluid (CSF) from patients with several forms of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease with dementia, Lewy body dementia, vascular dementia (VaD), and Creutzfeldt-Jakob disease. However, whether HFABP in CSF is a stable biomarker or if it can help predict conversion from mild cognitive impairment (MCI) to AD or VaD has not been well studied. To address the role of HFABP in neurodegeneration, we analyzed CSF levels of HFABP in 96 AD patients and 65 controls and also in 170 patients with MCI with an average follow up time of 5.7 years. For the stability analysis, two CSF samples were collected from 52 AD patients with a six month interval in between. HFABP levels in CSF were very stable over the six month period (r = 0.93, p < 0.001). Furthermore, the CSF levels of HFABP were significantly elevated in AD compared with controls after adjustments for age and gender (p < 0.001). They were also elevated in the patients with MCI that subsequently converted to AD or VaD compared with those that remained stable (p < 0.001 and p < 0.05, respectively). However, ROC curve analysis showed that HFABP had lesser predictive value in determining conversion from MCI to AD and VaD than A beta(42), t-tau, and p-tau. In conclusion, HFABP seems to be a stable CSF biomarker that reflects neuronal cell death in several neurodegenerative disorders, including early stages of AD and VaD.

Department/s

  • Clinical Memory Research
  • Computational Biology and Biological Physics - Undergoing reorganization
  • MultiPark: Multidisciplinary research focused on Parkinson´s disease

Publishing year

2013

Language

English

Pages

673-679

Publication/Series

Journal of Alzheimer's Disease

Volume

34

Issue

3

Document type

Journal article

Publisher

IOS Press

Topic

  • Neurology

Keywords

  • Alzheimer's disease
  • biomarker
  • cerebrospinal fluid
  • dementia
  • HFABP
  • vascular dementia

Status

Published

Research group

  • Clinical Memory Research

ISBN/ISSN/Other

  • ISSN: 1387-2877